GlassScriptPhysician profile
Tonya Adams
NPI 1861472862
$13,272.88
in general payments reported to CMS, 2019-2025
40 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $533 · 2021: $1,052 · 2022: $1,218 · 2023: $5,722 · 2024: $2,285 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,407 · Consulting Fee: $4,170 · Education: $85.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,406.54 |
| Consulting Fee | $4,170.00 |
| Education | $85.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,615.33 | 2019-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $2,488.67 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,141.65 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $594.63 | 2019-2025 | |
| Celgene Corporation | $584.25 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $374.66 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $239.13 | 2019-2025 | Sucraid |
| Braintree Laboratories, INC. | $228.35 | 2021-2025 | Suflave, Sutab |
| Genzyme Corporation | $175.90 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $168.90 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $151.72 | 2021-2025 | |
| Celltrion USA INC. | $142.07 | 2024-2025 | Zymfentra, Vegzelma |
| Intercept Pharmaceuticals, INC. | $137.30 | 2020-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $108.67 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $102.90 | 2024-2025 | Vowst, Zenpep |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.